S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
OTCMKTS:BPMUF

Basilea Pharmaceutica (BPMUF) Stock Price, News & Analysis

$40.75
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$40.75
$40.75
50-Day Range
$38.60
$41.00
52-Week Range
$38.60
$40.75
Volume
N/A
Average Volume
N/A
Market Capitalization
$482.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BPMUF stock logo

About Basilea Pharmaceutica Stock (OTCMKTS:BPMUF)

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.

BPMUF Stock Price History

BPMUF Stock News Headlines

Basilea Pharmaceutica AG (BSLN)
Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
Basilea To Buy Preclinical Antibiotics Program From Spexis
Basilea provides portfolio status update
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Basilea announces accelerated loan repayment
Basilea Pharma Submits NDA For Antibiotic Ceftobiprole
Basilea Pharmaceutica Posts FY Profit
See More Headlines
Receive BPMUF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Basilea Pharmaceutica and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:BPMUF
CIK
N/A
Employees
147
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$175.50 million
Cash Flow
$1.13 per share
Book Value
($1.83) per share

Miscellaneous

Free Float
N/A
Market Cap
$482.89 million
Optionable
Not Optionable
Beta
0.65

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. David Veitch (Age 59)
    Chief Executive Officer
    Comp: $1.26M
  • Mr. Adesh Kaul (Age 50)
    Chief Financial Officer
  • Dr. Gerrit Hauck Ph.D. (Age 60)
    Chief Technology Officer
  • Dr. Laurenz Kellenberger Ph.D. (Age 57)
    Chief Scientific Officer
  • Dr. Marc Engelhardt M.D. (Age 60)
    Chief Medical Officer
  • Dr. Peer Nils Schroder
    Head of Corporate Communications & Investor Relations
  • Mr. Damian Heller (Age 58)
    General Counsel & Corporate Secretary
  • Mr. Andreas Kumin
    Head of Corporate Development
  • Ms. Ursula Eberhardt (Age 62)
    Head of Global Human Resources
  • Mr. Mark Jones (Age 56)
    Head of Project Management & Preclinical Development

BPMUF Stock Analysis - Frequently Asked Questions

How have BPMUF shares performed in 2024?

Basilea Pharmaceutica's stock was trading at $41.00 on January 1st, 2024. Since then, BPMUF shares have decreased by 0.6% and is now trading at $40.75.
View the best growth stocks for 2024 here
.

Are investors shorting Basilea Pharmaceutica?

Basilea Pharmaceutica saw a decrease in short interest in the month of February. As of February 29th, there was short interest totaling 215,600 shares, a decrease of 14.3% from the February 14th total of 251,600 shares. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days.
View Basilea Pharmaceutica's Short Interest
.

How do I buy shares of Basilea Pharmaceutica?

Shares of BPMUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Basilea Pharmaceutica have any subsidiaries?
The following companies are subsidiares of Basilea Pharmaceutica: Conec UK Limited.
Read More
This page (OTCMKTS:BPMUF) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners